NCT04463680View on ClinicalTrials.gov

Rifampin and the Contraceptive Implant

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions
ContraceptionTuberculosis
Interventions
DRUG

Rifampin 600 MG

Administered daily for 2 weeks

Trial Locations (1)

80045

University of Colorado Denver, Aurora

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT04463680 - Rifampin and the Contraceptive Implant | Biotech Hunter | Biotech Hunter